Your session is about to expire
Meloxicam vs Diclofenac
Introduction
For patients experiencing joint pain or inflammation due to conditions such as osteoarthritis and rheumatoid arthritis, certain drugs that inhibit the production of substances in the body known as prostaglandins can significantly reduce pain levels and improve mobility. Meloxicam and Diclofenac are two such medications commonly prescribed for these ailments. Both belong to a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs), which work by reducing inflammation in the body. Meloxicam operates by selectively inhibiting the COX-2 enzyme responsible for producing prostaglandins, thus making it less likely to cause stomach problems compared with some other NSAIDs. On the other hand, Diclofenac is classified as a non-selective inhibitor affecting both COX-1 and COX-2 enzymes but may offer more potent relief from acute forms of pain.
Meloxicam vs Diclofenac Side By Side
| Attribute | Mobic | Voltaren |
|---|---|---|
| Brand Name | Mobic | Voltaren |
| Contraindications | Should not be taken with aspirin, other NSAIDs, steroids, anticoagulants, SSRIs, or SNRIs | Should not be taken with aspirin, other NSAIDs, steroids, anticoagulants, SSRIs, or SNRIs |
| Cost | Approximately $0.20 to $0.60 per day for generic | Approximately $0.25 to $1 per day for generic |
| Generic Name | Meloxicam | Diclofenac |
| Most Serious Side Effect | Symptoms of heart disease such as chest pain, shortness of breath, or rapid heartbeat; severe stomach issues; liver problems; kidney problems | Signs of an allergic reaction; symptoms related to a stroke or heart attack; liver problems; kidney problems; high blood pressure |
| Severe Drug Interactions | Aspirin, other NSAIDs, steroids, anticoagulants, SSRIs, SNRIs | Aspirin, other NSAIDs, steroids, anticoagulants, SSRIs, SNRIs |
| Typical Dose | 7.5-15 mg/day | 50-100 mg/day, up to a maximum of 150 mg/day |
What is Meloxicam?
Meloxicam (also known by the brand name Mobic) and Diclofenac are both part of the class of medications called nonsteroidal anti-inflammatory drugs (NSAIDs). They were developed to help manage symptoms associated with various inflammatory conditions, such as arthritis. Meloxicam was first approved by the FDA in 2000. Much like Prozac's function within the brain, Meloxicam works at a cellular level to reduce specific enzymes (COX-2), leading to less production of chemical messengers known as prostaglandins which cause pain and inflammation. It is prescribed for osteoarthritis, rheumatoid arthritis, and juvenile idiopathic arthritis.
While both Meloxicam and Diclofenac work on reducing these prostaglandins, they have slightly different influences on them. Meloxicam selectively inhibits COX-2 more than COX-1, which potentially results in fewer gastrointestinal side effects common among NSAIDs that inhibit COX-1 strongly. Meanwhile, Diclofenac has balanced inhibition of both COX enzymes but may be linked with a higher risk of cardiovascular events compared to other NSAIDs.
What conditions is Meloxicam approved to treat?
Meloxicam is approved for the treatment of various types of arthritis:
- Osteoarthritis, a common form of arthritis that causes pain and inflammation in the joints
- Rheumatoid Arthritis, an autoimmune disease characterized by severe inflammation in the joints
- Juvenile idiopathic arthritis (for patients 2 years old or older)
How does Meloxicam help with these illnesses?
Meloxicam works to manage pain and inflammation by inhibiting the production of prostaglandins, chemicals that cause inflammation and increase pain signals in the body. It achieves this by blocking cyclooxygenase (COX) enzymes, specifically COX-2, which are responsible for producing prostaglandins. By reducing the levels of these inflammatory mediators, Meloxicam can alleviate symptoms associated with conditions like osteoarthritis or rheumatoid arthritis such as swelling, stiffness, and joint pain.
Diclofenac also acts on the same principle but it inhibits both COX-1 and COX-2 enzymes. This broad-spectrum inhibition might result in a stronger anti-inflammatory effect but also may lead to more pronounced side effects especially related to gastrointestinal health. Therefore, patients must carefully consider their individual needs and potential risks when choosing between Meloxicam and Diclofenac for managing their condition.
What is Diclofenac?
Diclofenac, marketed under several brand names such as Voltaren, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation caused by conditions like arthritis. It operates by inhibiting the production of prostaglandins in the body which are responsible for causing pain and inflammation. Diclofenac was first approved by the FDA in 1988. As it's not a steroidal anti-inflammatory drug, it does not have steroid-related side effects such as water retention or hormonal imbalance. Its lack of steroid properties means its side-effect profile is also different to that of steroids, particularly in that it does not cause weight gain or mood swings (common side-effects of steroids). The reduction in prostaglandin can be beneficial for treating inflammatory conditions especially in patients who do not respond well to "typical" steroidal drugs.
What conditions is Diclofenac approved to treat?
Diclofenac, a popular NSAID, has received approval for the treatment of various conditions involving pain and inflammation. These include:
- Osteoarthritis
- Rheumatoid arthritis
- Ankylosing spondylitis
- Migraines
- Acute gout attacks It can also be used to manage postoperative or acute trauma-related pain when opioid analgesics are not suitable or have failed to provide adequate relief.
How does Diclofenac help with these illnesses?
Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that works by reducing substances in the body that cause pain and inflammation. It mainly targets cyclooxygenase-2 (COX-2), an enzyme responsible for producing prostaglandins, which are key players in the inflammatory response. Unlike Meloxicam, Diclofenac also mildly inhibits COX-1, giving it a broader spectrum of action against inflammation and pain. However, this does mean it can have more gastrointestinal side effects than COX-2 selective NSAIDs like Meloxicam. Its use may be preferred when patients need stronger or more general relief from symptoms such as joint stiffness, swelling or acute injury-related pain. In comparison to Meloxicam, Diclofenac may provide faster and more potent relief under certain circumstances but always under careful consideration of potential side effects.
How effective are both Meloxicam and Diclofenac?
Both meloxicam and diclofenac are nonsteroidal anti-inflammatory drugs (NSAIDs) that have proven efficacies in managing symptoms of arthritis, including pain, swelling, and joint stiffness. They were initially approved by the FDA several years apart, with diclofenac being introduced first in 1988 followed by meloxicam in 2000. While both medications inhibit the cyclooxygenase (COX) enzymes to reduce inflammation, they vary slightly in their selectivity for these enzymes.
In a 2004 double-blind clinical trial comparing meloxicam to diclofenac among patients with rheumatoid arthritis or osteoarthritis; both drugs showed comparable efficacy in reducing disease symptoms and exhibited similar safety profiles. The study found no significant difference between groups treated with either drug regarding the degree of pain reduction or improvement of physical function.
A review published in Drug Safety journal reported that despite its effectiveness at relieving arthritic symptoms from the first week of treatment onward, concerns over gastrointestinal side effects such as ulcers and bleeding led some patients to favor other NSAIDs over diclofenac. However, it was noted that these side effects could be mitigated through co-administration with gastric protectants like proton pump inhibitors.
On the other hand, a meta-analysis conducted in 2015 suggested that while offering comparable pain relief as other NSAIDs like diclofenac for conditions such as osteoarthritis; meloxicam has been associated with fewer gastrointestinal complications making it potentially more tolerable for long-term use. Even so, just like any medication there is always potential risk involved hence it's typically recommended only after taking into account individual patient’s medical history and tolerance towards possible adverse events.
Related trials for meloxicam and diclofenac
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Meloxicam typically prescribed?
Oral dosages of Meloxicam range from 7.5-15 mg/day, but research suggests that a dosage of 7.5 mg/day is usually effective for treating osteoarthritis in most people. For rheumatoid arthritis or ankylosing spondylitis, the dose may be increased to 15mg per day if required by your doctor. Children and adolescents should have doses determined by their healthcare provider based on weight and condition being treated. The maximum daily dosage that should not be exceeded in any case is 15 mg/day.
At what dose is Diclofenac typically prescribed?
Diclofenac treatment typically begins with a dosage of 50-100 mg/day, divided into two or three doses around the clock. The dose can then be increased to a maximum of 150 mg/day, divided into three doses of 50 mg each and spaced about 8 hours apart. If no significant improvement is seen in symptoms after several weeks at the starting dosage, your doctor may suggest increasing it incrementally up to this threshold. As always, never self-adjust your medication dosages; any changes should be made under the guidance of your healthcare provider.
What are the most common side effects for Meloxicam?
Side effects that are commonly associated with Meloxicam include:
- Nausea and vomiting
- Gas, heartburn, or stomach pain
- Diarrhea or constipation
- Headache
- Dizziness or drowsiness (somnolence)
- Rash
- Itching or skin rash
While common side effects of Diclofenac can include:
-Nausea and vomiting -Diarrhea or constipation -Gas, bloating. indigestion (dyspepsia) -Dizziness, nervousness -Skin redness, itching or rash -Ringing in the ears
Remember to always contact your healthcare provider if you experience these symptoms persistently after taking either medication.
Are there any potential serious side effects for Meloxicam?
While both Meloxicam and Diclofenac are non-steroidal anti-inflammatory drugs (NSAIDs) used to relieve pain and reduce inflammation, they can cause different side effects. Serious side effects for Meloxicam can include:
- Symptoms of heart disease such as chest pain, shortness of breath or rapid heartbeat
- Signs of allergic reaction like difficulty breathing; swelling in the face, lips or throat; hives or rash
- Severe stomach issues: black stool, vomiting blood or what looks like coffee grounds
- Liver problems: nausea, upper stomach pain, fatigue, dark urine
- Kidney problems - little to no urination
For Diclofenac:
- Severe skin reaction: fever with sore throat and burning eyes; red/purple skin rash with blistering/peeling
- Digestive system distress: severe heartburn/stomach ache
- Any liver problem symptoms: loss of appetite leading to weight loss; jaundice (yellowing of the skin); itching
If you experience any serious side effects while taking either medication you should contact your doctor immediately.
What are the most common side effects for Diclofenac?
Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), has been known to cause the following side effects:
- Upset stomach or nausea
- Heartburn or indigestion
- Diarrhea or constipation
- Headache or dizziness
- Ringing in the ears
- Skin redness, itching, rash, or blisters
- Increased blood pressure and fluid retention
-Unusual weight gain
-Sleep problems such as insomnia
-In rare cases, it may lead to liver problems
Are there any potential serious side effects for Diclofenac?
While Diclofenac is usually well-tolerated, it can cause serious side effects in some cases. Be sure to seek immediate medical attention if you experience any of the following:
- Signs of an allergic reaction, such as hives; difficulty breathing; swelling in your face or throat
- Symptoms related to a stroke or heart attack including chest pain spreading to your jaw or shoulder, sudden numbness or weakness on one side of the body, slurred speech
- Liver problems - nausea, upper stomach pain, itching, tired feeling, flu-like symptoms, loss of appetite and jaundice (yellowing of the skin or eyes)
- Kidney problems - little to no urinating; painful or difficult urination; swelling in your feet or ankles; feeling tired
- High blood pressure - severe headache blurred vision pounding in neck/ears anxiety shortness breath If you notice any of these symptoms after taking Diclofenac stop using it immediately and consult with a healthcare professional.
Contraindications for Meloxicam and Diclofenac?
Both meloxicam and diclofenac, as well as other non-steroidal anti-inflammatory drugs (NSAIDs), can potentially exacerbate symptoms in people with heart disease or increase the risk of serious gastrointestinal side effects. If you notice an escalation of existing conditions, or appear to be developing new health problems while taking these medications, seek immediate medical attention.
Neither meloxicam nor diclofenac should be taken if you are also using aspirin, other NSAIDs, steroids, anticoagulants, selective serotonin reuptake inhibitors (SSRIs), or serotonin-norepinephrine reuptake inhibitors (SNRIs). Always inform your healthcare provider about all medications that you're currently taking; some may need time to clear from your system before starting treatment with meloxicam or diclofenac to avoid dangerous interactions.
How much do Meloxicam and Diclofenac cost?
For the brand name versions of these drugs:
- The price for 30 tablets of Mobic (meloxicam, 15 mg) averages around $140, which works out to roughly $4.66/day.
- The price for 30 tablets of Voltaren (diclofenac, 75 mg) averages about $200, working out to approximately $6.67/day.
Thus, if you are taking a standard dosage range for both medications, then the brand-name Mobic is less expensive on a per-day treatment basis. However, cost should not be the primary consideration in determining which of these drugs is right for you as their efficacy and side effects can vary.
For the generic versions meloxicam and diclofenac costs are significantly lower:
- Meloxicam (7.5 - 15 mg tablets) is available in packs from 30 capsules upwards with approximate costs around $0.20 to $0.60 per day depending on your dose.
- Diclofenac (50 - 100 mg tablets), similarly comes in packs starting from at least quantity of thirty; its daily cost ranges from around $0.25 up to about $1 depending on dosage amount and retailer pricing strategies. Please remember that prices can vary greatly between different pharmacies and may also depend upon any health insurance coverage you might have.
Popularity of Meloxicam and Diclofenac
Meloxicam, available as a generic medication and under the brand name Mobic, was estimated to have been prescribed to approximately 18 million Americans in 2020. Meloxicam accounted for nearly 20% of NSAID (Non-Steroidal Anti-Inflammatory Drug) prescriptions in the United States. While it's considered a COX-2 selective NSAID, similar to celecoxib or etoricoxib, meloxicam is not classified as one due to its partial selectivity only. The prescription rate for meloxicam has been increasing since FDA approval in 2000.
Diclofenac, including branded versions such as Voltaren and Cataflam, was prescribed about 6.5 million times during the same year in the USA. Diclofenac constitutes around 7% of all NSAID prescriptions and just over 3% of overall anti-inflammatory drug prescriptions across various classes used for pain relief like opioids or acetaminophen combinations. Unlike meloxicam which shows preference towards inhibiting COX-2 enzyme more than COX-1; diclofenac is non-selective and equally inhibits both enzymes leading to better efficacy but increased risk of gastrointestinal side effects.
Conclusion
Both Meloxicam and Diclofenac have a long history of usage in patients with inflammatory conditions such as osteoarthritis and rheumatoid arthritis, supported by numerous clinical studies indicating their efficacy over placebo treatments. Sometimes these medications may be combined, subject to careful consideration by a healthcare provider since they also carry contraindications with one another. With divergent mechanisms of action in that meloxicam primarily inhibits COX-2 more than COX-1 whereas diclofenac inhibits both enzymes equally, they are prescribed under different circumstances.
Meloxicam is often considered the first-line treatment option due to its lower risk for gastric side effects compared to diclofenac; on the other hand, diclofenac might be used as an adjuvant therapy or chosen for patients who did not respond well to other NSAIDs or have specific pain management needs.
Both drugs are available in generic form which represents significant cost savings especially for uninsured patients. Both meloxicam and diclofenac may require an adjustment period meaning effects may not be noticeable immediately after initiation of therapy.
The side effect profile between the two drugs is similar overall but each has unique risks: while meloxicam tends less toward gastrointestinal issues than does diclofenac, both can cause cardiovascular issues particularly at high doses or prolonged use. For this reason, all NSAID users should closely monitor their symptoms when starting treatment and seek medical help immediately if they experience chest pain, shortness of breath or sudden weakness/numbness.
Other Trials to Consider
Popular Categories
Popular Guides
Learn More About These Treatments
Refrences
- Goei Thè, H. S., Lund, B., Distel, M. R., & Bluhmki, E. (1997, July). A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Osteoarthritis and Cartilage. Elsevier BV.http://doi.org/10.1016/s1063-4584(97)80024-6
- Menassé, R., Hedwall, P. R., Kraetz, J., Pericin, C., Riesterer, L., Sallmann, A., … Jaques, R. (1978, January). Pharmacological Properties of Diclofenac Sodium and Its Metabolites. Scandinavian Journal of Rheumatology. Informa UK Limited.http://doi.org/10.3109/03009747809097211
- Todd, P. A., & Sorkin, E. M. (1988, March). Diclofenac Sodium. Drugs. Springer Science and Business Media LLC.http://doi.org/10.2165/00003495-198835030-00004
- Price-Forbes, A. N., Callaghan, R., Allen, M. E., & Rowe, I. F. (2005, April 12). A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines. Rheumatology. Oxford University Press (OUP).http://doi.org/10.1093/rheumatology/keh642
- Fleischmann, R., Iqbal, I., & Slobodin, G. (2002, October). Meloxicam. Expert Opinion on Pharmacotherapy. Informa Healthcare.http://doi.org/10.1517/14656566.3.10.1501
- Furst, D. E. (1997, June). Meloxicam: Selective COX-2 inhibition in clinical practice. Seminars in Arthritis and Rheumatism. Elsevier BV.http://doi.org/10.1016/s0049-0172(97)80049-2
- Schattenkirchner, M. (1997, March). Meloxicam:a selective COX-2 inhibitor non-steroidal anti-inflammatory drug. Expert Opinion on Investigational Drugs. Informa Healthcare.http://doi.org/10.1517/13543784.6.3.321
- Mustofa, M., Suryawati, S., Dwiprahasto, I., & Santoso, B. (1991, August). The relative bioavailability of diclofenac with respect to time of administration. British Journal of Clinical Pharmacology. Wiley.http://doi.org/10.1111/j.1365-2125.1991.tb03890.x
- Dalal, D., Dubreuil, M., Peloquin, C., Neogi, T., Zhang, Y., Choi, H., & Felson, D. (2017, October 13). Meloxicam and risk of myocardial infarction: a population-based nested case–control study. Rheumatology International. Springer Science and Business Media LLC.http://doi.org/10.1007/s00296-017-3835-x
- Adebajo, A. O., & Eastmond, C. J. (1992, March). Hepatotoxicity to several nonsteroidal anti-inflammatory drugs with diclofenac induced histological changes. Clinical Rheumatology. Springer Science and Business Media LLC.http://doi.org/10.1007/bf02207099
- Schapira, D., Bassan, L., Nahir, A. M., & Scharf, Y. (1986, January 1). Diclofenac-induced hepatotoxicity. Postgraduate Medical Journal. Oxford University Press (OUP).http://doi.org/10.1136/pgmj.62.723.63